Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20593366 | 1.00 | CA14 (0.38) | CA14CA12CA2MEN1KMT2A | |
| SCHEMBL20593369 | 1.00 | CA14 (0.38) | CA14CA12CA2MEN1KMT2A | |
| SCHEMBL21385385 | 0.91 | MEN1 (0.40) | CA14CA12CA2MEN1KMT2A | |
| SCHEMBL17881260 | 0.91 | MEN1 (0.40) | CA14CA12CA2MEN1KMT2A | |
| SCHEMBL17877380 | 0.89 | CA14 (0.38) | CA14CA12CA2MEN1KMT2A | |
| SCHEMBL23854196 | 0.80 | CA14 (0.38) | CA14CA12CA2MEN1KMT2A | |
| SCHEMBL934416 | 0.80 | CA14 (0.38) | CA14CA12CA2MEN1KMT2A | |
| SCHEMBL5837182 | 0.80 | CA14 (0.38) | CA14CA12CA2MEN1KMT2A | |
| SCHEMBL28485053 | 0.79 | CTSK (0.33) | CA14CA12CA1HDAC1HDAC2 | |
| SCHEMBL18281954 | 0.79 | CTSS (0.34) | CA14CA12CA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181142-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS INC (US) | 2020-06-11 | — | — | US | disclosed |
| US-20190031653-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2019-01-31 | — | — | US | disclosed |
| US-10077264-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-09-18 | — | — | US | disclosed |
| EP-3240787-A2 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | Novira Therapeutics Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-9550779-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031653-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | CA14 2350/4885CA12 2545/4885CA2 3717/4885 |
| US-10077264-B2 | Derivatives and methods of treating hepatitis B infections | HAVCR2, PYGL, HCCS | CA14 2350/4885CA12 2545/4885CA2 3717/4885 |
| US-20200181142-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | CA14 2350/4885CA12 2545/4885CA2 3717/4885 |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | CA14 2350/4885CA12 2545/4885CA2 3717/4885 |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | CA14 2350/4885CA12 2545/4885CA2 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.